Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Automated Tool Detects Early Warning Signs of Breast Cancer

By LabMedica International staff writers
Posted on 10 Oct 2025

Branching is a vital biological process that enables organs like the lungs, kidneys, and breasts to perform complex functions. More...

In female mammary glands, most branching occurs after birth—during puberty and pregnancy—when milk ducts expand to prepare for breastfeeding. Disturbances in this process are closely linked to breast cancer risk. However, studying mammary gland branching is difficult and time-consuming, as traditional methods require slicing tissue and manually counting ducts under a microscope. Now, scientists have developed a new analytical tool that quantifies mammary gland branching quickly and accurately. The tool could be used to study how hormonal changes and treatments affect mammary glands or even to detect early warning signs of breast cancer.

Researchers at Cold Spring Harbor Laboratory (CSHL, Cold Spring Harbor, NY, USA) created the Mammary Gland Network analysis tool, or MaGNet, to study the structure of mouse mammary glands. The system applies principles of network theory to biological imaging, translating the complex architecture of milk ducts into quantifiable data points. Using MaGNet, researchers can measure the total length of ductal trees, the number of ducts and alveoli, and the degree of branching in stained images of breast tissue. The process is supported by NetworkX software, which plots the structures as interconnected networks for computational analysis.

The idea for MaGNet was inspired by a mathematical model originally applied to plants, which was adapted to analyze mammary gland branching patterns. In practice, users trace the ducts in digital tissue images and use computer code to calculate network parameters. The tool eliminates inconsistencies caused by manual analysis and allows scientists to visualize the entire ductal architecture at once. The study describing this method was published in the Journal of Mammary Gland Biology and Neoplasia.

Currently, MaGNet has been tested in mice, but its flexible design means it can be modified for other branching systems. The tool’s developers anticipate that it could be used to investigate how hormones, infections, or life stages—such as pregnancy and menopause—affect mammary gland development and cancer risk. In addition to basic research, MaGNet could support early disease detection by identifying subtle architectural changes in breast tissue before tumors become visible through imaging or physical examination.

The technology represents an important step toward improving breast health monitoring through quantitative, data-driven methods. With further development, MaGNet may contribute to understanding how branching abnormalities signal early cancer development, ultimately advancing diagnostic capabilities and preventative strategies in oncology.

“We’re always hunting for warning signs that arise before you can feel a lump or see anything on a mammogram or ultrasound,” said Steven Lewis, a graduate researcher in the Dos Santos Lab at Cold Spring Harbor Laboratory. “Imagine an automated tool could say there’s no tumor yet, but there are changes detectable. That’s our hope, our dream.”

Related Links:
CSHL


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.